Research ArticlesFirst-Pass Metabolism of Omeprazole in Rats
References and Notes (20)
- et al.
Lancet
(1982) - et al.
Lancet
(1983) - et al.
Gastroenterology
(1983) - et al.
Biochem. Pharmacol.
(1985) - et al.
Nature
(1981) - et al.
Scand. J. Gastroenterol.
(1985) - et al.
Drugs
(1982) - et al.
Deutsche Med. Wochen.
(1985) - et al.
Deutsche Med. Wochen.
(1985) - et al.
Engl. J. Med.
(1985)
Cited by (48)
Pediatric and Geriatric-Friendly Buccal Foams: Enhancing Omeprazole Delivery for Patients Encountering Swallowing Difficulties
2023, Journal of Pharmaceutical SciencesThe natural flavonoid myricetin inhibits gastric H<sup>+</sup>, K<sup>+</sup>-ATPase
2018, European Journal of PharmacologyCitation Excerpt :Additionally, myricetin is easily converted into various derivatives after being taken up by the body (Lin et al., 2012). In contrast, the reported bioavailability of omeprazole is 9.6–70% in human and experimental animals (Larsson et al., 1983; Stedman and Barclay, 2000; Watanabe et al., 1994). Proton pump inhibitors, including omeprazole, are widely used for the clinical treatment of gastric acid-related disorders (Schubert, 2010), but recent studies indicate that these inhibitors increase the risk of other diseases, including cardiovascular events (Cardoso et al., 2015), bone fracture (Leontiadis and Moayyedi, 2014), infection (Sultan et al., 2008), chronic kidney disease (Klatte et al., 2017), and dementia (Goldstein et al., 2017).
Oxidation and reduction of omeprazole on boron-doped diamond electrode: Mechanistic, kinetic and sensing performance studies
2017, Sensors and Actuators, B: ChemicalCitation Excerpt :Pharmaceutical formulations of omeprazole are available as tablets and capsules (containing pure omeprazole or its magnesium salt) or a powder (sodium salt of omeprazole) for intravenous applications. The most of OMZ pharmaceutical formulations for oral use are enteric-coated, due to rapid degradation of the tablet or capsule only in the acidic media of the stomach [4]. For the determination of OMZ in pharmaceutical and biological samples several analytical methods have been developed.
Instantaneous enteric nano-encapsulation of omeprazole: Pharmaceutical and pharmacological evaluation
2014, International Journal of PharmaceuticsCitation Excerpt :Omeprazole seems to be well absorbed from the gastrointestinal tract (GIT). However, its oral bioavailability in humans is about 40–50% due to a marked first-pass metabolism before entering the systemic circulation (Watanabe et al., 1994). Omeprazole is widely used in doses of 20–80 mg in treatment of duodenal and gastric ulcers, reflux oesophagitis and in the Zollinger–Ellison Syndrome (Clissold and Campoli-Richards, 1986; Watanabe et al., 1994).
Comparative study of preparation and characterization of enteric and enhanced release omeprazole microparticles
2011, Journal of Drug Delivery Science and TechnologyImprovement of the in vitro release of omeprazole from suppository bases using Kollicoat IR
2010, Journal of Drug Delivery Science and Technology